title: [The influence of IL-2 on the immunologic function of the NPC patients treated with radiotherapy and chemotherapy].
abstract: OBJECTIVE
  To investigate the combining therapy which not only have cured effect but also can uphold and improve the NPC patient's immunity function after radiotherapy and chemotherapy.
  
  
  METHODS
  90 cases randomly divided into 3 groups 1. Local group (local injected with IL-2 + radiotherapy + chemotherapy); 2. General group (ivdrip with IL-2 + radiotherapy + chemotherapy); 3. Convention group (radiotherapy + chemotherapy). Checked and observed the immunity function around the immunotherapy and after the radiotherapy and chemotherapy.
  
  
  RESULTS
  Cellular immunity of 3 groups are lower and humoral immunity are hypetuntion than normal person. After treated with IL-2 the cellular immunity improves but there's no great change of the humoral immunity. The immune status of the immune groups have not obvious change than before radiotherapy, at the same time, the cellular immunity of the convention group cut down and the humoral immunity doesn't change obviously.
  
  
  CONCLUSIONS
  1. It has some effect to uphold and improve the NPC patient's immunity function to treat with small dosage of IL-2 before radiotherapy and chemotherapy, general treatment is better than local injection; 2. The three therapies have not great influence on the patient's humoral immunity.
authors.affiliation: ENT Department, Guangxi Provincial People's Hospital, Nanning 530021.
authors.forename: Y
authors.initials: Y
authors.lastname: Si
authors.forename: P
authors.initials: P
authors.lastname: Wang
authors.forename: W
authors.initials: W
authors.lastname: Jiao
authors.forename: R
authors.initials: R
authors.lastname: Zhou
authors.forename: Z
authors.initials: Z
authors.lastname: Zhang
authors.forename: Z
authors.initials: Z
authors.lastname: Deng
authors.forename: Z
authors.initials: Z
authors.lastname: Chen
authors.forename: Z
authors.initials: Z
authors.lastname: Tao
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000276:immunology* / Q000532:radiotherapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007376:Interleukin-2 / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000532:radiotherapy
chemical_list: D007376:Interleukin-2